Madonna Rosalinda
Center for Aging Sciences and Translational Medicine (CeSI-MeT), "G. d'Annunzio" University, Chieti, Italy; The Texas Heart Institute and Center for Cardiovascular Biology and Atherosclerosis Research, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, United States.
Rev Esp Cardiol (Engl Ed). 2017 Jul;70(7):576-582. doi: 10.1016/j.rec.2017.02.001. Epub 2017 Feb 27.
Heart failure due to antineoplastic therapy remains a major cause of morbidity and mortality in oncological patients. These patients often have no prior manifestation of disease. There is therefore a need for accurate identification of individuals at risk of such events before the appearance of clinical manifestations. The present article aims to provide an overview of cardiac imaging as well as new "-omics" technologies, especially with regard to genomics and proteomics as promising tools for the early detection and prediction of cardiotoxicity and individual responses to antineoplastic drugs.
抗肿瘤治疗导致的心力衰竭仍然是肿瘤患者发病和死亡的主要原因。这些患者通常之前没有疾病表现。因此，需要在临床表现出现之前准确识别有发生此类事件风险的个体。本文旨在概述心脏成像以及新的“组学”技术，特别是基因组学和蛋白质组学，它们作为早期检测和预测心脏毒性以及个体对抗肿瘤药物反应的有前景的工具。
